MedWatch

Genmab CFO targets 39-percent recurring revenue growth in 2022

Anthony Pagano, CFO of Genmab, is expecting revenue growth of 39 percent from the products marketed by the company itself in 2022.

Photo: Lars Møller / Genmab / PR

In the current financial year, Danish biotech firm Genmab is hoping for a 39-percent growth in revenue from products it markets itself, meaning the company’s recurring revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs